<DOC>
	<DOCNO>NCT00470353</DOCNO>
	<brief_summary>RATIONALE : The use cholecalciferol calcium carbonate may keep colon cancer come back patient colon cancer remove surgery . PURPOSE : This randomized clinical trial study two different dos cholecalciferol compare well work give together calcium carbonate treat patient colon cancer remove surgery .</brief_summary>
	<brief_title>Cholecalciferol Calcium Carbonate Treating Patients With Colon Cancer That Has Been Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare antiproliferative effect 2 different dos cholecalciferol ( i.e. , vitamin D3 ) combination calcium carbonate proliferative label index patient resect colon cancer . Secondary - Compare effect dose serum level 25-OH-D3 , 1,25-OH-D3 , 24,25-OH-D3 , calcium , parathyroid hormone patient . - Determine safety high-dose cholecalciferol patient 2 year . - Compare effect dose several biological marker ( i.e. , cyclin D1 , protein kinase C , vitamin D receptor , p21 , p27 ) rectal mucosa patient . OUTLINE : This randomize , pilot study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral low-dose cholecalciferol daily oral calcium carbonate twice daily . - Arm II : Patients receive oral high-dose cholecalciferol daily calcium carbonate arm I . Treatment arm continue 2 year absence disease progression unacceptable toxicity . All patient undergo sigmoidoscopy colonoscopy 4 quadrant mucosal biopsy baseline 6 month study treatment . After 6-month mucosal biopsy , patient arm I switch high-dose cholecalciferol arm II . Patients undergo blood , urine , tissue collection periodically study pharmacokinetic , pharmacodynamic , and/or histopathological analysis . Serum collect monthly 3 month every 3 month assess change serum level vitamin D vitamin D metabolite ( i.e. , 1,25-OH-D3 ; 25-OH-D3 ; 24,25-OH-D3 ) , well change calcium parathyroid hormone , BUN , creatinine , electrolytes , phosphorus level . Urine collect every 3 month assess change urine calcium creatinine level hypercalciuria . Tissue biopsies normal endorectal mucosa collect baseline 6 month study treatment evaluate IHC proliferative index , vitamin D receptor staining , p21 , p27 , cyclin D1 , protein kinase C. PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : History colon cancer Underwent resection clinical remission ≥ 1 year No inflammatory bowel disease No familial adenomatous polyposis PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 1 year No genitourinary stone within past 5 year No severe comorbid condition , uncompensated heart failure active uncontrolled infection No history hypercalcemia No active colostomy No contraindication sigmoidoscopy mucosal biopsy PRIOR CONCURRENT THERAPY : No prior rectal surgery abdominoperineal resection At least 1 month since prior vitamin D calcium supplementation Prior vitamin D supplemental intake ≤ 800 IU per day At least 1 year since prior chemotherapy No prior radiotherapy pelvis No concurrent active anticoagulation Patients stop anticoagulation therapy time mucosal biopsy eligible No concurrent supplemental calcium vitamin D</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage I colon cancer</keyword>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
</DOC>